Kivorent News

Wednesday, November 18, 2026

Health techNews

FDA clears Bracco and Avicenna.AI software that flags brain aneurysms on CT scans

Bracco and Avicenna.AI said on November 13 that the FDA cleared UPTUNITY | Aneurysm, AI software that flags suspected brain aneurysms on head CT angiography and tracks known ones between scans.

Docket, covering health regulation and AI in care
, 2 min read

2FDA 510(k) clearances behind the product

What to know

  • The product rests on two 510(k) clearances: K262062 for detection and K262147 for measuring and tracking known aneurysms.
  • It reads head CT angiography and flags suspected saccular aneurysms larger than 3 mm, giving their location and size to the reading specialist.
  • Avicenna.AI will lead U.S. sales; the companies plan to show it at RSNA 2026 in Chicago and gave no launch date.

Milan-based imaging company Bracco and AI developer Avicenna.AI said on November 13 that the U.S. Food and Drug Administration has cleared UPTUNITY | Aneurysm, software that uses AI to find and measure brain aneurysms on CT scans. It is the first product in Bracco's new UPTUNITY line of AI clinical decision support tools, according to the companies' release and a report in Imaging Technology News (ITN).

What the FDA cleared

The product is built on two separate 510(k) clearances, ITN reported. The detection tool, sold as UPTUNITY | Aneurysm Detection, was cleared under the name CINA-Aneurysm (K262062). The follow-up tool, sold as UPTUNITY | Aneurysm Management, was cleared as CINA-Aneurysm+ (K262147). A 510(k) clearance means the FDA found the device substantially equivalent to one already on the market; it is not the same as approval. Our explainer on clearance, approval and De Novo covers the difference.

What the software does

Both tools work on head CT angiography (CTA), a scan that images the arteries of the brain with contrast dye. The detection tool looks for suspected saccular aneurysms, the common berry-shaped bulges in an artery wall, larger than 3 mm. It reports whether one is present, where it is and how big it is. The companies describe it as a concurrent reading aid: it runs inside the radiologist's workflow while they read the scan, rather than replacing that read.

The management tool is for patients already known to have an aneurysm. It produces measurements and compares them across exams so doctors can see whether an aneurysm is changing over time. Bracco's Cosimo DePinto told ITN that "the clinical decision stays where it belongs: with the radiologist." The release says the software does not replace a full patient evaluation or a physician's review.

Neither the release nor ITN reported accuracy figures, such as sensitivity or specificity, for the product. The FDA's 510(k) summaries for the two clearances would hold the performance testing the agency reviewed.

Who sells it and when

Avicenna.AI, founded in 2018, will lead promotion and distribution in the U.S. The two companies announced their partnership in March 2026, ITN reported. They said they are preparing for a commercial launch but gave no date. They plan to show the product at RSNA 2026, the radiology meeting in Chicago from November 29 to December 3.

Unruptured brain aneurysms are common and often found by chance: ITN, citing the Brain Aneurysm Foundation, put the figure at about one in 50 U.S. adults.

Why it matters

Radiology is where most FDA-cleared AI tools sit, and this clearance adds one aimed at a finding that is small, easy to miss and serious if it ruptures. It also shows a pattern in how these tools are being sold: as separate detection and follow-up products, each with its own clearance. What the companies have not published yet is how well it performs, and recent research has questioned how often AI device updates show clinical benefit. For other AI clinical software moves this month, see Wolters Kluwer's deal for AgileMD and the FDA's clearance of PulseAI's smartwatch ECG software.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

FDA and health regulationDigital health and AI in care

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.